The company
Dianthus Therapeutics, Inc.
DNTH · Nasdaq
DNTH stood above a rising 150-day average in 48 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 20.1% below that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Not moving yet
- Weeks in an uptrend
- out for 4
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $134.1M
- Officials’ trades on record
- 0
- Institutions holding
- 256 (+24)
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 48 of 52 weeks.
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
Open-market buys above the line and sales below, in dollars.
Congress and officials
No member of Congress or official has disclosed a trade in it.
Insiders
| Who | Did | Shares | Traded |
|---|---|---|---|
| Edward CarrCHIEF ACCOUNTING OFFICER | sold | 7,928at $100.43 | 17 Sep 2026filed 18 Sep 2026 |
| Edward CarrCHIEF ACCOUNTING OFFICER | sold | 6,771at $101.37 | 17 Sep 2026filed 18 Sep 2026 |
| Edward CarrCHIEF ACCOUNTING OFFICER | sold | 3,501at $102.39 | 17 Sep 2026filed 18 Sep 2026 |
| Edward CarrCHIEF ACCOUNTING OFFICER | sold | 1,100at $103.20 | 17 Sep 2026filed 18 Sep 2026 |
| Edward CarrCHIEF ACCOUNTING OFFICER | sold | 700at $104.39 | 17 Sep 2026filed 18 Sep 2026 |
| Simrat RandhawaEVP, Head of R&D | sold | 2,600at $105.19 | 1 Sep 2026filed 3 Sep 2026 |
| Simrat RandhawaEVP, Head of R&D | sold | 7,215at $106.25 | 1 Sep 2026filed 3 Sep 2026 |
| Simrat RandhawaEVP, Head of R&D | sold | 13,309at $106.74 | 1 Sep 2026filed 3 Sep 2026 |
| Simon ReadDirector | sold | 2,778at $117.55 | 19 Aug 2026filed 19 Aug 2026 |
| Simon ReadDirector | sold | 70at $107.11 | 10 Aug 2026filed 11 Aug 2026 |
| Simon ReadDirector | sold | 737at $108.17 | 10 Aug 2026filed 11 Aug 2026 |
| Simon ReadDirector | sold | 831at $108.95 | 10 Aug 2026filed 11 Aug 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.
| Manager | Shares | Change |
|---|---|---|
| FMR LLCadded · filed 13 Aug 2026 | 8,199,893$799.3M | +432,207+5.6% |
| BlackRock, Inc.added · filed 7 Aug 2026 | 4,123,822$402.0M | +948,119+29.9% |
| WELLINGTON MANAGEMENT GROUP LLPadded · filed 14 Aug 2026 | 3,229,882$314.8M | +634,099+24.4% |
| Fairmount Funds Management LLCunchanged · filed 14 Aug 2026 | 2,537,191$247.3M | 00.0% |
| STATE STREET CORPadded · filed 7 Aug 2026 | 2,357,440$229.8M | +958,527+68.5% |
| VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026 | 2,159,568$210.5M | +128,319+6.3% |
| Avidity Partners Management LPunchanged · filed 14 Aug 2026 | 2,104,184$205.1M | 00.0% |
| Octagon Capital Advisors LPreduced · filed 14 Aug 2026 | 1,841,667$179.5M | -105,000−5.4% |
| TCG Crossover Management, LLCunchanged · filed 14 Aug 2026 | 1,676,624$163.4M | 00.0% |
| FRED ALGER MANAGEMENT, LLCadded · filed 14 Aug 2026 | 1,302,493$127.0M | +140,570+12.1% |
Everyone who traded it
Same industry
Government contracts
No federal award is tied to it.
From its SEC filings
Analyst forecasts
No analyst forecasts yet.